NDAORALTABLET
Approved
Feb 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
EDARBI (azilsartan kamedoxomil) by R-Pharm US is angiotensin-converting enzymes (ace, kinase ii). Approved for hypertension in adults, to lower blood pressure, hypertension and 1 more indications. First approved in 2011.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EDARBI (azilsartan kamedoxomil) is an oral angiotensin II receptor blocker (ARB) approved in 2011 for the treatment of hypertension in adults. The drug is a prodrug that is rapidly converted to active azilsartan, which selectively blocks AT1 receptors to inhibit vasoconstriction and aldosterone secretion. EDARBI represents an alternative to ACE inhibitors with a mechanism independent of bradykinin degradation, positioning it as a direct renin-angiotensin system antagonist.
$0.0BPart D
1.9 years to LOEMechanism of Action
angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan…
Indications (4)
Worked on EDARBI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.